ISTO Technologies specializes in orthobiologic solutions aimed at enhancing patient healing through innovative products. The company offers a comprehensive portfolio that includes the Magellan® Autologous Concentration System, which facilitates the creation of various autologous therapies such as Platelet Rich Plasma (PRP) and Concentrated Bone Marrow Aspirate. Additionally, ISTO provides a range of allograft products derived from donor tissue, categorized under the Influx™ line, which includes advanced offerings like ProteiOS, Fibrant, SPARC, PLUS, and Sponge. These products are designed to address specific patient and procedural challenges, providing customizable options for surgeons across different specialties.

In the realm of synthetic solutions, ISTO's InQu® line features cell-friendly, biosynthetic bone grafts that have demonstrated clinical efficacy in promoting faster bone fusion compared to traditional methods. The company is committed to continuous innovation, focusing on high standards and actively engaging with healthcare professionals to develop products that meet evolving needs. Notably, their Fibrant line of allografts utilizes proprietary technology to create longer and stronger fibers, enhancing cell attachment and overall performance. This dedication to research and development underscores ISTO's mission to improve patient outcomes through advanced biologic solutions.

United States

Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, joined forces under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company's best-in-class product offerings include Arteriocyte's market-leading Magellan® Autologous Platelet Separator and Isto's bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; and Influx™, a natural bone-graft material.

ISTO Technologies

Company Details